Prospective survey of efficacy and safety of Deep Brain Stimulation for severe involuntary movement in Tourette syndrome

Prospective survey of efficacy and safety of Deep Brain Stimulation for severe involuntary movement in Tourette syndrome - Prospective survey of Deep Brain Stimulation for severe involuntary movement in Tourette syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030592

Enrollment

Registered

2017-12-27

Start date

2017-12-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with severe involuntary movement in Tourette syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with Dystonic tic who are to undergo DBS covered by national Health Care Insurance System 2.Patients over 12 years old. If patients under 12 years old are applicable to the surgery of severe involuntary movement, medical ethical committee will deliberate it. 3.Patients signed an informed consent document. 4.Patient's legal representatives sign an informed consent document if patients are minor. 5.Patients meet DSM-4 for clinical diagnose criteria of Tourette syndrome 6.Patients with severe involuntary movement meet over 35/50 in YGTSS. 7.More than 6 months medication or psychological therapy failed to improve the symptoms or those were intolerant because of side effects. 8.If patients are life-threatening condition by involuntary movements even though YGTSS sore or treatment period or so don't meet inclusion criteria, they are to undergo the surgery after approval by medical ethical committees.

Exclusion criteria

Exclusion criteria: 1.High risk patients with physical or mental complications (severe cardiovascular disorder, severe respiratory dysfunction, severe blood diseases, epilepsy, medical history of severe head injuries, severe stroke, severe neurodegenerative diseases, autism, schizophrenic, manic depression, drug addictions, pregnant, breast-feeding, female patients of child-bearing potential 2.Patients ineligible to the study based on investigator's decision.

Design outcomes

Primary

Measure	Time frame
YGTSS(Yale Global Tic Severity Scale)	—

Secondary

Measure	Time frame
Modified Rush Tic Rating Scale, Yale-Brown Obsessive-Compulsive Score, neuropsychological test(WAIS-3,WMS-R,BD1-2,MMPI), Cortical activities measured by NIRS	—

Countries

Japan

Contacts

Public ContactTakashi Morishita

Fukuoka University Hospital Department of Neurosurgery

tmorishita@fukuoka-u.ac.jp092-801-1011

Outcome results